I'll be straight with you: I haven't used peptides.
I've thought about them. I've read about them. I've had plenty of conversations at the gym with guys who swear by them. One of my training partners recently told me his shoulder pain — something he'd been dealing with for years, through physical therapy and cortisone shots and all of it — significantly reduced after a few weeks on BPC-157 and TB-500.
That kind of result gets your attention.
At the same time, the peptide world is noisy. The internet is full of people who sound like they're selling something, and the line between genuine clinical insight and biohacker marketing isn't always obvious. So when Shawn Ryan sat down with Dr. Craig Koniver on episode 330 of the Shawn Ryan Show — a physician who has administered over 50,000 peptide treatments and runs one of the most clinically experienced practices in the country — I paid close attention.
What follows is my honest breakdown of that conversation: what Koniver covers, what the actual research says, where the hype outruns the evidence, and where the skeptics might be selling something short too.
Who Is Dr. Craig Koniver?
Koniver runs Koniver Wellness in Charleston, South Carolina. He walked away from conventional disease-based medicine two decades ago and rebuilt his practice around what he calls performance optimization and longevity. His patient list includes Navy SEALs, Fortune 500 executives, professional athletes, and politicians.
At 46, he had a near-fatal portal vein thrombosis — a blood clot in the main vein feeding the liver — that also showed a mass on his pancreas. He describes what happened in the hospital while waiting for his MRI as a profound spiritual experience, a moment of total peace that he credits to his faith. The mass turned out to be benign or misread entirely. He's been on a blood thinner ever since and doesn't apologize for it — a nuance worth noting from someone often categorized as anti-pharmaceutical.
His credibility on peptides isn't theoretical. It comes from clinical volume over more than a decade — seeing what works, what doesn't, and what the side effects actually look like in real people.
What Peptides Actually Are
Koniver's explanation is clean and worth starting with: peptides are chains of amino acids. Forty or fewer amino acids — it's a peptide. Forty-one or more — it's a protein. They're small signaling molecules. Your body already makes them.
His analogy for how they work versus pharmaceuticals is useful: "I think of peptides as like whispering to your cells, and pharmaceuticals like a sledgehammer." The pharmaceutical model gives everyone the same dose, expects side effects, and overrides biology. Peptides, in his framing, work with your biology — they signal, nudge, and facilitate rather than force.
That distinction matters for how you think about them.
The Main Categories Koniver Covers
Growth hormone-releasing peptides — compounds like ipamorelin, tesamorelin, and sermorelin. These travel to the part of the brain that releases growth hormone, bind the growth hormone receptor, and stimulate a pulse of GH. As we age, growth hormone output declines. It's anabolic — it helps you heal, recover, and rebuild. These peptides get you most of the way there without using synthetic GH directly. Anti-inflammatory peptides — BPC-157 and TB-500 are the ones most people in fitness circles have heard of. Koniver describes BPC-157 as "very anti-inflammatory to the soft tissue — the tendons and ligaments." He says he'd argue that anyone who works out a lot should consider BPC-157. Nervous system peptides — DIHEXA, Selank (CELANC), Cerebrolysin. These target the brain and nervous system. Selank acts on the GABA system — the same receptors alcohol and benzos affect — and has a calming effect. Koniver describes the combination of Dihexa and Selank as "like a natural Adderall" in nasal spray form. Mitochondrial peptides — MOTS-c, Humanin, SS-31. These support cellular energy production and mitochondrial architecture. Circadian rhythm peptides — Epithalon and Pinealon, which help regulate melatonin and sleep cycling.It's a wide field. Koniver is clear that the approach should be individualized — understanding a patient's goals, their history, their biology — rather than stacking as many peptides as possible.
BPC-157 and TB-500: What the Research Actually Shows
Here's where I have to be honest about the gap between the clinical enthusiasm and the published evidence.
BPC-157 has over 100 published preclinical studies — mostly in rats and rodents, primarily from a Croatian research group, running back to the 1990s. The results across those animal studies are consistently impressive: accelerated healing of tendons, ligaments, muscle, and gut tissue. Reduced inflammation. Nerve repair. The biological mechanisms are plausible and well-described.
The human evidence is a different story.
As of mid-2026, there are only a handful of published human studies involving BPC-157. The most cited: a 2025 IRB-approved safety pilot study involving two adults who received IV infusions up to 20mg with no adverse events; a small observational study of knee pain patients where about 87% reported significant relief; and a 2024 study of bladder pain where 80–100% of 12 patients showed symptom improvement. A 2025 systematic review in the American Journal of Sports Medicine covered the full literature through mid-2024 and found consistent preclinical support but sparse human data — and no randomized controlled trials for any indication.
TB-500 is in a similar position. The full-length protein it's derived from (thymosin beta-4) has better human evidence — including a 2025 cardiac study showing improved outcomes in STEMI patients — but TB-500 itself, the synthetic fragment most people use, has no published human clinical trials. As of 2026, it's classified as an FDA Category 2 bulk drug substance, meaning it cannot legally be compounded by licensed pharmacies in the US.
What this means practically: The absence of human trial data doesn't mean these compounds don't work. It means we don't have the formal confirmation yet. The preclinical mechanisms are real. Anecdotal and clinical evidence — including from practitioners like Koniver with serious patient volume — is real. But anyone who presents BPC-157 or TB-500 as proven in humans the way, say, creatine monohydrate is proven, is getting ahead of the science.My training partner's shoulder is better. That's meaningful. It's also one data point.
The Angiogenesis Question
Shawn Ryan asks Koniver directly about a concern I've seen circulate online: that BPC-157 might cause cancer by promoting angiogenesis — the formation of new blood vessels that tumors use to feed themselves.
Koniver's response is measured. He acknowledges the mechanism: BPC-157 does promote angiogenesis. But he pushes back on the cancer conclusion. Angiogenesis is also how your body heals a blocked artery, or repairs damaged tissue. It's a normal biological process. The theoretical link to cancer would require existing cancer to be present — the BPC wouldn't cause it, but could theoretically feed it.
He's clear: in over a decade of clinical use with large patient numbers, he hasn't seen cancer develop. He also acknowledges that long-term longitudinal studies don't exist, and that absence of evidence isn't proof of safety — only that serious signals haven't emerged in clinical practice.
This is a legitimate gray area. It's not a reason to panic, but it's a reason to be thoughtful — particularly if you have any personal or family history of cancer.
The Gray Market Problem
This is one of the most important parts of the conversation and one that doesn't get enough attention in fitness circles.
Koniver explains that the FDA has placed several peptides — including BPC-157 — in a restricted category that prevents them from being compounded by licensed pharmacies. That regulatory action created the gray market: online vendors selling research-grade or unverified peptides directly to consumers, no prescription, no oversight, unknown sourcing.
"This is why the gray market of peptides took off," he says, "so people can go online and get their own peptides with no oversight from sources that are probably contaminated or illegitimate."
He's not saying all gray market peptides are dangerous. He's saying the oversight is gone, and that matters. Contamination, incorrect dosing, misidentified compounds — these are real risks when you're injecting something with no pharmaceutical-grade verification.
If you're going to explore peptides, source matters. A compounding pharmacy that is FDA-registered and state board-inspected is a different thing than a website that ships lyophilized powder in a vial with no accountability. Koniver is explicit about this in the episode.
The Biohacker Influencer Problem
One of the most refreshing parts of the episode is Koniver pushing back on the maximalist optimization culture that has colonized a lot of the longevity space.
He describes a pattern he sees constantly in his practice: people coming in "taking 47 supplements, doing sauna and cold plunge every single day, taking 16 peptides." His reaction isn't admiration. It's concern. "It's almost as if they've become so fragile that they can't even lead their life."
This resonates with me directly. The biohacker influencer model — the idea that if you're not doing everything, you're doing nothing — creates anxiety, not health. It turns self-optimization into another source of stress. And stress is one of the primary enemies of the recovery and longevity these people say they're chasing.
Koniver's alternative framing: individualize, go slowly, listen to your body, and let direct experience be the guide. Don't stack sixteen peptides because someone on a podcast said to. Start with one thing, see how you respond, and build from there.
That's a philosophy I can get behind — and it mirrors how I think about training. Consistency with a few well-chosen things beats complexity with a lot of poorly-understood things, every time.
Where Koniver and I Agree
Sleep is the foundation. Koniver's number one recommendation for a healthy 45-year-old? Fix sleep first. He uses theanine, ashwagandha, and glycine — natural compounds — before any peptide or pharmaceutical. This is basic, unglamorous, and true. I've written about this elsewhere and I'll keep saying it: no supplement stack covers for consistently bad sleep. Hormones matter more than most people acknowledge. Koniver talks at length about testosterone for men and thyroid for women. His point about lab reference ranges is worth sitting with: those ranges are built from population averages of people who are mostly overweight, medicated, and metabolically compromised. Being "normal for your age" isn't the standard worth optimizing toward. GLP-1s are useful tools, not magic. He's measured on semaglutide — thinks it's effective for weight loss when used carefully, starting low, going slow. His concern is at higher doses he's seeing anhedonia — loss of pleasure, decreased interest in food, sex, social connection. The weight loss works. The dopamine system implications are worth watching. You're not going to make someone younger. He says it plainly: "The goal is never to make someone younger. The goal is to help people feel their best so they can perform their best at any age." That's the right frame.My Honest Take
I'm not closing the door on peptides. The mechanisms are real, the clinical volume practitioners like Koniver have accumulated is real, and the anecdotal evidence from people I personally know and trust is hard to dismiss.
What I'm not going to do is treat them as proven in humans the way creatine or protein are proven. The gap between the animal data and the human clinical evidence is significant. That gap may close — there are trials in progress and regulatory reviews ongoing. But right now, anyone who tells you BPC-157 is definitely going to fix your shoulder is getting ahead of the science, even if it worked for your gym friend.
The things I know work: sleep, protein, progressive training, creatine, magnesium, zone 2 cardio, deloads, managing stress. These aren't exciting. They're also not complicated, they're not expensive, and the evidence base is unambiguous.
Peptides may have a real place in that toolkit — particularly for tissue repair, for people who've tried the fundamentals and are looking for additional tools, and for those working with a qualified physician who has actual clinical experience with these compounds.
But the fundamentals come first. They always come first.
If you're curious about peptides, the Shawn Ryan Show episode 330 with Dr. Craig Koniver is worth the full listen. He's one of the most experienced practitioners in this space and he's more measured than most.
Want help building a training and recovery approach that's grounded in what actually works? Let's talk._